Showing papers by "Henry G. Burger published in 2001"
TL;DR: Sexual responsivity is adversely affected by both aging and the menopausal transition, and other domains of female sexual functioning were significantly adversely affected when the women became postmenopausal.
314 citations
TL;DR: To evaluate the effects of a defined formula of Chinese medicinal herbs (CMH) on menopausal symptoms, a large number of patients were diagnosed with at least some of the symptoms of post-menopausal symptoms.
Abstract: Objective To evaluate the effects of a defined formula of Chinese medicinal herbs (CMH) on menopausal symptoms. Design A double-blind randomised placebo-controlled trial. Methods Between August 1998 and April 1999, 55 postmenopausal Australian women recruited from an urban population completed 12 weeks of intervention with either a defined formula of CMH (n = 28) or placebo (n = 27) taken twice daily as a beverage. Main outcome measures The primary end-point was change in frequency of vasomotor events (hot flushes and night sweats). The secondary end-points were changes in score for the domains measured in the Menopause Specific Quality of Life (MENQOL) Questionnaire. Results There was a reduction in average weekly frequency of vasomotor events with CMH (-15%; 95% CI, -31% to +1%) and with placebo (-31%; 95% CI, -42% to -21%). The difference between groups favoured the use of placebo; however, this was not significant (P=0.09). Although significant reductions in scores for the various domains of the MENQOL Questionnaire were observed for both CMH and placebo, there were no significant differences between the two treatment groups for any domain. There was evidence for effect modification by previous use of natural therapies for the vasomotor, physical and sexual domains of the MENQOL Questionnaire: women with no prior use of natural therapies for their menopausal symptoms responded to therapy, whereas prior users did not. Conclusions The defined formula of CMH was no more effective than placebo in reducing vasomotor episodes in Australian postmenopausal women, or in improving any of the four symptom domains in the MENQOL Questionnaire. Three of the MENQOL Questionnaire domains were modified by prior use of natural therapies. This finding has implications for future studies.
72 citations
TL;DR: A new inhibin immunoassay (total inhibin ELISA) has been developed with the intention of widespread clinical application and readily detects granulosa cell and mucinous tumours.
52 citations
TL;DR: Women who developed IFG during the menopausal transition exhibited significantly higher levels of body fatness and dyslipidemia, premenopausally, compared with the women who did not develop IFG.
Abstract: OBJECTIVES: To investigate: (i) the incidence of impaired fasting glycaemia (IFG) developed over 5 y in a population-based sample of Australian-born women; (ii) prospectively the factors which are associated with the development of IFG; (iii) the association of the menopausal transition with the onset of IFG and an increase in serum insulin concentrations. DESIGN AND METHODS: A total of 265 women (110 pre-, 138 peri-, 17 postmenopausal) participants in the longitudinal phase of the Melbourne Women's Midlife Health Project, aged 46–57 and with normal fasting plasma glucose concentrations at the time of the initial measure, were interviewed, had physical measurements and blood taken annually over a 5 y follow-up period. RESULTS: During the study period 43 women (16%) recorded a fasting glucose concentration of ≥6.1 mmol/l (IFG). Women who recorded IFG prospectively had, at the time of the initial measure when fasting glucose concentrations were normal: higher body mass index (BMI), trunk skinfold thicknesses, waist and hip circumferences (P<0.005), lower SHBG, higher free androgen index and serum insulin concentrations (P<0.05), higher systolic blood pressure, serum triglyceride and lower HDL-cholesterol concentrations (P<0.05) than women whose fasting glucose concentrations remained normal. The onset of IFG was not triggered by the menopausal transition or hormone use. Changes in insulin concentration were associated with changes in BMI (P<0.05). CONCLUSION: Women who developed IFG during the menopausal transition exhibited significantly higher levels of body fatness and dyslipidemia, premenopausally, compared with the women who did not develop IFG. The menopausal transition did not have an effect on the development of IFG, but weight gain during this period was associated with an increase in insulin concentration.
38 citations
TL;DR: The pragmatic approach is to recommend standard therapy with estrogen and progestogen for the management of menopausal symptoms and to recommend longer term hormone replacement in the light of the individual’s needs and current data with regard to efficacy for protection from osteoporosis and cardiovascular disease.
Abstract: The major biologically active circulating estrogen in both males and females is estradiol (E2). Circulating E2 is a product of the ovarian granulosa cell and the testicular Leydi
37 citations
TL;DR: There is a profound decline in estradiol in the 3–4 years surrounding final menses, and this results in menopausal symptoms and bone loss, and the late menopausal transition is marked by 60–90 days of amenorrhoea and frequent prolonged and often anovulatory cycles.
27 citations
6 citations